Acalabrutinib Regimen Demonstrates Combinatorial Benefit in MCL
Tycel Phillips, MD, questioned how the regimen of acalabrutinib, bendamustine, and rituximab would compare with taking the drugs separately in mantle cell lymphoma.
Related Articles
Everolimus Plus Lanreotide Shows PFS Benefit in Unresectable/Recurrent GEP-NETs
The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
Metronomic Capecitabine Improves Upon AIs in HR+/HER2- Metastatic Breast Cancer
The phase 3 MECCA trial represents the largest data set investigating the efficacy of metronomic chemo-endocrine combination therapy in metastatic breast cancer, according to researchers.
IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML
Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.
Rathmell steps down at NCI as Trump team considers candidates to replace her Wafik El-Deiry, Harvey Risch have been interviewed – The Cancer Letter
W. Kimryn Rathmell has stepped down as NCI director, opting to hand her resignation to the Biden administration over facing the uncertainties that Trump and…
Sunvozertinib Under FDA Priority Review for NSCLC With EGFR Exon 20 Insertion Mutations
The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.
Dexamethasone Plus Physical Activity May Reduce Cancer-Related Fatigue
Combining aerobic and resistance-based physical activity with dexamethasone may improve quality of life and reduce the effects of fatigue.
Fill | SSO 2025 Surgical Oncology Bowl
To join a team for the 2025 SurgOnc Bowl, please complete the following questionnaire. For more information and the rules of engagement, please visit this…
The long road to unbiased estimates of pancreatic cancer incidence in the hereditary breast and ovarian cancer syndrome
The determination of unbiased cancer risk estimates in hereditary breast and ovarian cancer syndrome (HBOC) poses several challenges. The article by Katona and colleagues is…
Dana-Farber Brigham Cancer Center Recognized for Exceptional Outcomes in Adult Donor Stem Cell Transplants for Fifth Consecutive Year
Stem cell transplant programs at the Dana-Farber Brigham Cancer Center received outstanding reviews from the CIBMTR.
MDS highlights from ASH 2024
Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses his key myelodysplastic syndrome (MDS) highlights from this year’s ASH meeting.…
